Lantern Pharma

Clinical-stage AI-driven precision-oncology biotech. Three clinical small-molecule candidates (LP-300, LP-184 "zirdafulven", LP-284) that are largely rescued molecules others failed to develop, selected by the RADR machine-learning platform; plus a wholly-owned subsidiary (Starlight Therapeutics) for CNS/brain cancers and an early antibody-drug-conjugate (ADC) program. (10-K FY2025)

AI-native precision-oncology biotech running 3 clinical candidates (LP-300, LP-184 "zirdafulven", LP-284) selected by the RADR platform, plus the spun-out Open Medicine AI (OMAI) co-scientist platform (formerly withZeta.ai).

• monetization model: No product revenue; clinical-stage biopharma funded by equity, grants, and interest. Future monetization expected via drug sales and/or licensing/collaboration. (FY2023 10-K, Business/Liquidity; sec.gov ; accession 0001493152-24-010342; later FY2025 10-K UNKNOWN)
• revenue mix: No product revenue disclosed; no segment revenue note. (FY2023 10-K, segment/revenue notes; same URL/accession)
• who pays: No commercial buyer today. Equity investors and grant agencies fund operations. Future economic buyer expected: payers/providers or pharma partners. (FY2023 10-K, Business/Liquidity; same URL/accession)
• margin_value_capture: No gross margin (pre-revenue); operating losses. Value accrues via drug IP and RADR platform if approved/partnered. (FY2023 10-K, MD&A; same URL/accession)

• customer classes: UNKNOWN (no commercial customers disclosed). Future potential: Pharma & Biotech, Health Systems & Providers, Payers & Insurers. (FY2023 10-K, Business; same URL/accession)

Lantern Pharma Inc.

I cannot provide a verified revenue mix. Any percentage would be fabricated without the income statement and segment note from the relevant 10-K or 10-Q.

Expected structure, to be verified:

• Product sales: needs primary source validation
• Collaboration or grant revenue: needs primary source validation
• Interest/investment income: needs primary source validation
• Other revenue: needs primary source validation

Likely reality for a clinical-stage biotech: revenue is minimal or absent; operating losses are driven by R&D and G&A.

• Gross margin: not meaningful if there is no product revenue. If any collaboration revenue exists, the exact gross margin needs primary source validation.
• Operating margin: expected to be deeply negative because of clinical trial and R&D expense. The exact operating margin or R&D/G&A split needs primary source validation.

The long-term monetization model is presumably:

• future oncology drug sales;
• out-licensing and milestone payments;
• possible research collaborations or data partnerships.

This is an industry-standard biotech model, but LTRN-specific contract terms, milestones, or partnership revenue needs primary source validation.

There are no current commercial drug payers if the company has no approved product. Future payer mix would likely include:

• Medicare and commercial health insurers;
• hospital and oncology practice formularies;
• specialty pharmacies;
• ex-US national payers, if drug candidates are approved abroad.

No LTRN-specific payer contracts can be cited here.

I could not open LTRN’s filings in this session. Therefore, I cannot name any customer or collaboration counterparty that is actually disclosed in a 10-K or 10-Q.

No customer names are verified. Do not treat any name from memory as sourced.

None verifiable. A clinical-stage biotech generally does not have commercial customers. Any collaboration partners named in SEC filings are not retrievable in this session.

If clinical development succeeds, likely buyer archetypes include:

• academic medical centers;
• community oncology practices;
• hospital pharmacy and therapeutics committees;
• Medicare and private insurers;
• specialty pharmacies and distributors;
• large pharma partners for commercialization or out-licensing.

These are generic oncology-market buyers, not LTRN-specific.

No buyer/collaborator name can be cited here. The instruction is to never invent a customer.

Pre-revenue — $0 product revenue. FY2025 R&D expense $11.51M, net loss −$17.12M, operating cash flow −$15.68M (XBRL companyfacts, CIK 0001763950). Q2 2026 loss from operations ~$3.5M, down ~25% YoY (8-K ex99.1, 08-14). Cash + marketable securities ~$7.4M at 2026-06-30 (8-K ex99.1); cash-only $6.66M (XBRL). Shares outstanding 12.76M (Q2 10-Q).

If AI-native discovery is a real bottleneck, Lantern is a pure-play bet on the discovery-compression economics with 3 clinical assets + a platform (OMAI) already advanced at ~$1–2.5M/program.

• RADR platform: >200B data points (molecular, drug-efficacy, historical-trial, literature, phenotypic, pathway data) with ML-driven biomarker selection (10-K FY2025).
• FIH economics: "advanced from initial A.I. insights to first-in-human clinical trials in 2–3 years and at approximately $1.0–$2.5 million per program" (10-K). Management's industry-norm comparator: 5–10 years and $25–100M (Q2 2026 PR).
• LP-300 (HARMONIC, EGFR exon-21 L858R NSCLC): median PFS 8.9 mo (6-cycle completers, n=9) vs 8.4 mo (full L858R cohort, n=16); HR 0.37 (95% CI 0.15–0.89) favoring L858R; 77% clinical benefit rate; FDA reviewed Phase-2 protocol amendment (single-arm L858R focus, 6→8 cycles) with no objection (8-K ex99.1, 08-14).
• LP-184 (zirdafulven): EMA cleared investigator-initiated Phase 1b/2 bladder-cancer trial (Rigshospitalet, Denmark; dual biomarker PTGR1 + DNA-damage-repair deficiency); FDA cleared TNBC Phase 1b/2 (HRD+); USPTO Notice of Allowance on a 3-gene patient-selection signature across 4 solid-tumor indications (8-K ex99.1, 08-14).
• Open Medicine AI (OMAI) spun out (Aug 2026), wholly owned by Lantern, with board-approved commercial licensing agreements; AI Centers of Excellence in Dallas + Bengaluru (Q1 2026); OMAI intends to raise capital at the OMAI level; dedicated informational call mid-Sept 2026 (8-K ex99.1, 08-03).
• Ownership: Bios Equity Partners, LP holds a 13D position (13D/A filings, CIK 0001813314) — a life-science crossover/activist holder.

• Net-loss-vs-cash-burn distortion (correcting the prior note): Q2 FY2026 operating loss −$3.51M (−25% YoY) vs net loss −$7.07M (SEC companyfacts, CIK 0001763950). The ~$3.56M gap is attributed largely to non-cash warrant accounting (management attribution in Q2 coverage). Actual operating cash flow decelerated: Q1 −$3.77M → Q2 −$2.94M (derived: H1 −$6.71M minus Q1 −$3.77M, companyfacts) — cash burn improved even as reported net loss widened.
• Refined runway ≈ 2.5 quarters: $7.4M cash + marketable securities (06-30) ÷ ~$3.0M/quarter cash burn → exhaustion ~mid-January 2027 (vs the prior note's ~2.1 quarters / late-Q4-2026). Modest improvement; does NOT remove the financing overhang — the company is already liquidating marketable securities (H1 investing cash flow +$4.94M) to fund operations.
• Cox regression (partial mitigation of the small-n risk): the Q2 call added that a Cox regression controlling for race, gender and TP53 status "identified L858R as an independent predictor of benefit" (LP-300 HARMONIC) — but the CEO explicitly cautioned the cohorts are small and "not powered for statistical significance."
• Revealed-preference signal on the AI platform: Empery Asset Management led the May registered direct offering ($4.4M gross proceeds closed 05-14, $2.06/share) AND its CIO Ryan Lane stated withZeta.AI is Empery's "preferred platform for AI-assisted biopharma due diligence" — a paying institutional fund using the product it financed (8-K EX-99.1, 08-03).
• OMAI value-accrual is two-sided: OMAI is wholly owned by Lantern but "intends to raise capital at the OMAI level," which dilutes LTRN's stake; the commercial licensing agreements are intercompany. How existing LTRN shareholders participate in OMAI economics is the unresolved question the mid-Sept call must answer.
• Incremental pipeline items absent from the prior note: ZetaOmics computational-biology module launched (07-08); LP-284 received FDA Orphan Drug Designation for soft-tissue sarcomas (earlier 2026); Starlight STAR-001 (LP-184 + spironolactone) advancing in brain cancers.

the moat compresses only the discovery→first-in-human slice (~36x cost / ~3x time by company figures), while FDA-mandated Phase 1–3 clinical development is irreducible by AI. The binding constraint on the EQUITY is the ~2.5-quarter runway and the unresolved OMAI value-accrual — not the discovery physics.

\[

S = (20{,}000{,}000 - 4{,}000{,}000) + (60 - 24) \times 200{,}000

\]

\[

S = 16{,}000{,}000 + 36 \times 200{,}000

\]

\[

S = 16{,}000{,}000 + 7{,}200{,}000

\]

\[

S = 23{,}200{,}000

\]

Under these assumptions, the illustrative economic benefit is $23.2 million per accelerated or rescued program.

Vary \(C_{base}\):

Vary \(T_{RADR}\):

Vary \(C_{month}\):

The calculation is useful only as a framework. It does not prove LTRN’s platform is actually faster or cheaper. A verified deep-dive would need:

• LTRN’s own R&D spend per program from 10-K/10-Q;
• time from candidate identification to IND or Phase 1;
• peer benchmarks from competitor filings;
• cost-of-capital inputs with named-institution or academic sources.

Until those are sourced, this calculation is not load-bearing and should carry near-zero confidence.